NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported a 4 percent increase in its third quarter revenues, as the company beat the consensus Wall Street estimate on the top line but missed on the bottom line.

For the three months ended Sept. 30, Sigma-Aldrich took in $664 million in revenues, up from $639 a year ago, and edging out the average analyst estimate of $661.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.